HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

RELATED LINKS
Free Membership
Premium Home
Zacks #1 Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
Mutual Funds
ETFs
RSS Feed
Profit from the Pros
Subscription Services
FTM Trader
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


VRTX: VERTEX PHARMACEUTICALS INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

VERTEX PHARMACEUTICALS INC (NASD)
VRTX 64.85 0.76 (1.19%) Vol.  1,967,212 16:00 ET

Zacks Rank: 3 - Hold

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 63.67 - 64.94
52wk Low - High 26.50 - 66.10
Avg Volume 5,936,591
Industry MED-BIOMED/GENE
Market Cap 13.48 B
Div - Yield 0.00 - 0.00
PE (forward) 25.48
PEG Ratio N/A
Current Year Est. 2.52
EPS Last Year 0.91
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 05/23/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
VERTEX PHARMACEUTICALS INC VRTX 3
AFFYMAX INC AFFY 1
AGENUS INC AGEN 1
HESKA CORP HSKA 1
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.59
ABR (Last Week) 1.59
# of Recs in ABR 17
Average Target Price 70.06
Rank in Industry 100 out of 176
More Brokerage Recommendations


NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate VRTX?

Buy Sell
Find out what the Zacks Community
thinks of VRTX at PeopleAndPicks.com
 
ZACKS COMMENTARY FOR VRTX
Zacks Equity Research: Report for VRTX
May 23, 2012
Zacks Blog: Vertex Pharma's CF Drug Outperforms
May 08, 2012
Zacks Blog: Company News for May 08, 2012
May 08, 2012
Zacks Blog: Merck Beats by a Penny; Affirms View
Apr 27, 2012
Zacks Blog: Pharma & Biotech Stock Outlook - April 2012
Apr 26, 2012
Zacks Blog: Vertex Reports Positive Data on Incivek
Apr 20, 2012
Zacks Blog: Vertex' HCV-HIV Treatment Impresses
Mar 21, 2012
Zacks Blog: Positive Data on VRTX Combo Therapy
Feb 29, 2012
More Zacks Commentary
NEWS
BRIEF: European panel backs Vertex cystic fibrosis drug - Story Title - Comtex
May 25, 2012
Potential Vertex Pharmaceuticals (VRTX) Trade Has 9.83% Downside Protection - Story Title - Comtex
May 25, 2012
Vertex Announces Webcast of its Presentations at Two Investor Conferences - Story Title - Comtex
May 25, 2012
Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis - Story Title - Comtex
May 25, 2012
Vertex Receives European CHMP Positive Opinion for KALYDECO??? (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis - Benzinga
May 25, 2012
Perception, Opportunity in Volatility - Research & Analysis on VertexPharmaceuticals Incorporated and Huntington Bancshares Incorporated - Story Title - Comtex
May 24, 2012
Vertex Appoints David Altshuler to its Board of Directors - Benzinga
May 24, 2012
Vertex Appoints David Altshuler, M.D., Ph.D., to its Board of Directors - Story Title - Comtex
May 24, 2012
More News
EARNINGS ESTIMATES
  This Quarter
06/2012
Next Quarter
09/2012
This Year
12/2012
Next Year
12/2013
Average Estimate 0.65 0.72 2.52 2.71
Number of Estimates 14 14 14 15
Low Estimates 0.45 0.50 1.89 1.35
High Estimate 0.81 0.88 3.07 4.78
Year Ago EPS -0.82 0.57 -0.49 2.52
EPS Growth 179.09% 26.44% 613.41% 7.80%

More Estimates

COMPANY DESCRIPTION
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Full Company Report
FINANCIALS
EPS TTM .91
Sales 1410.63
Net Income 297.26
Price/Earnings 70.43
Price/Book 12.62
Price/Cash Flow N/A
Price/Sales 7.59


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research